Compounded Semaglutide Dosage: A Comprehensive Guide to Yo

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide dosing typically follows a four-week titration schedule: 0.25mg, 0.5mg, 0.75mg, and 1mg weekly. Clinical studies show this stepwise approach minimizes gastrointestinal side effects while allowing the body to adapt to GLP-1 receptor activation. Dosing may continue upward to 2.4mg based on clinical response and provider assessment.

Choosing the right semaglutide dose requires more than a standard protocol. Your metabolic profile, baseline GLP-1 receptor function, and individual tolerance shape how your body responds. PlexusDx supports precision-wellness by helping you understand these factors before conversations with your healthcare provider about optimal dosing.

Standard Titration Schedules and Clinical Rationale

The classic semaglutide titration progresses weekly: Week 1 receives 0.25mg, Week 2 receives 0.5mg, Week 3 receives 0.75mg, and Week 4 receives 1mg. This gradual escalation mirrors how GLP-1 receptors in the gut and brain upregulate over time. Slower titration also allows assessment of nausea, appetite suppression, and gastrointestinal tolerance.

After reaching the 1mg maintenance phase, some patients may increase to 1.5mg or 2.4mg weekly based on clinical goals and tolerability. Research indicates that approximately 50-60% of patients require doses above 1mg to achieve meaningful weight reduction. Your provider may adjust frequency or pause titration if side effects emerge or if treatment response plateaus.

Biomarkers and Metabolic Factors That Influence Dosing Decisions

Beyond standard protocols, several biomarkers and metabolic factors may influence how your body responds to semaglutide doses. Fasting glucose, insulin levels, GLP-1 receptor signaling capacity, and baseline BMI all contribute to treatment response variability. Understanding these factors supports more targeted conversations with your healthcare provider about whether standard titration timing fits your clinical context.

Biomarker or Factor	Potential Dosing Implications
Fasting insulin >12 mIU/mL	May indicate insulin resistance; provider may assess tolerance at standard 1mg or consider slower titration
FTO genetic predisposition (rs9939609)	Associated with increased appetite signaling; may inform expectations about dose-dependent appetite suppression
GLP-1R genetic variation (rs6923761)	Relates to baseline GLP-1 receptor sensitivity; may contextualize individual dose-response patterns
Baseline BMI >40	Typically shows dose-dependent response; many patients benefit from doses of 1.5-2.4mg weekly

Individual Response Patterns and Dose Adjustments

Not all patients follow identical dose progression. Some experience robust appetite suppression at 0.75mg and may not require escalation. Others reach 1mg and see minimal appetite change, prompting provider consideration of higher doses. Response depends on GLP-1 receptor density, stomach emptying rates, and individual baseline metabolic function.

Dose adjustments should always involve your healthcare provider. If nausea or vomiting emerges, your provider may pause titration or reduce dose temporarily rather than stopping treatment entirely. Conversely, if you reach maintenance dose without appetite suppression benefit, your provider may explore whether continuation, escalation, or alternative approaches align with your clinical goals.

Safety Considerations and Provider-Guided Dosing

Semaglutide dosing requires medical oversight. Compounded semaglutide is prepared by licensed 503A pharmacies under pharmacist supervision—not FDA-approved as branded formulations are, but made to pharmaceutical standards. Your provider should assess for contraindications: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis risk, or severe kidney disease.

Dehydration, electrolyte shifts, and medication interactions should be monitored as doses increase. Starting with the standard 0.25mg titration schedule gives your provider baseline safety data. If you have diabetes, blood pressure fluctuations, or concurrent GLP-1 agents, your provider may adjust dosing frequency or timing. Open communication about side effects and response ensures your dose aligns with your health profile, not just treatment objectives.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP-1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—genes that regulate appetite signaling and GLP-1 pathway sensitivity. These predispositions may help provide context for how your body might respond to different semaglutide doses, supporting more informed conversations with your provider about dosing strategy.

The genetic test reveals predispositions in peptide pathways, not exact medication response. A GLP-1R variant may suggest your baseline receptor sensitivity, but does not predict whether 1mg or 2.4mg will be optimal for you. This insight should be interpreted with a qualified healthcare provider alongside your clinical history, metabolic labs, and treatment tolerance.

Understanding your genetic and biomarker context empowers you to ask informed questions during dosing decisions. When your provider discusses titration timing or dose adjustments, you can reference how your genetic profile might influence GLP-1 pathway activation, supporting a collaborative, evidence-informed approach to finding your optimal compounded semaglutide dose.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the standard starting dose of compounded semaglutide?

Standard dosing begins at 0.25mg weekly, increasing by 0.25mg each week over four weeks to reach 1mg maintenance. Your provider may recommend a different schedule based on your medical history, tolerability, and clinical goals.

How long does the titration schedule typically take?

The classical titration spans four weeks, reaching 1mg by Week 4. Some providers extend this to 5-6 weeks if you experience significant nausea or gastrointestinal side effects, allowing gradual GLP-1 receptor adaptation.

Can I start at a higher dose to speed up weight loss?

Starting higher doses increases nausea, vomiting, and gastrointestinal side effects without evidence of faster weight loss. Gradual titration allows your body to adapt and helps your provider monitor safety and tolerance effectively.

What if I experience nausea during the titration phase?

Nausea commonly emerges during titration and often resolves within days. Your provider may recommend staying at your current dose longer, reducing injections temporarily, or adjusting eating patterns. Rarely, dose reduction is necessary.

How does the PlexusDx Precision Peptide Genetic Test inform dosing decisions?

The test identifies predispositions in GLP-1R, GIPR, FTO, and MC4R genes that may relate to appetite signaling and pathway sensitivity. This insight can support conversation with your provider about expected dose-response patterns, not predict exact medication outcomes.

Compounded Semaglutide Dosage: A Comprehensive Guide to Your Weight Loss Journey